Brand-name drug
Subvenite price, strengths & recalls
Brand of lamotrigine (generic)
Pharmacies pay $2.06 for 30 tablets of Subvenite 150 mg tablet this week, and from $0.81 to $687.43 across its 5 priced strengths and forms. The generic, lamotrigine, costs pharmacies from $0.81. It is in shortage (being discontinued). It has 13 recalls on record, none ongoing. Its official label last changed on October 21, 2026.
Being discontinuedBrand- Fair cash price
- $12.87
- Strengths
- 5
- Makers
- 1
- Updated
- Nov 11
Subvenite price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 10 mg/mL oral suspension Brand | $2.86 | $687.43 / 240 mL | ||
| Orange (for patients not taking carbamazepine, phenytoin, phenobarbital, primidone, or valproate) pack Brand | Not priced this week | |||
| 25 mg tablet Brand | $0.0270 | $0.81 / 30 tablets | ||
| 100 mg tablet Brand | $0.0483 | $1.45 / 30 tablets | ||
| 150 mg tablet Brand | $0.0688 | $2.06 / 30 tablets | ||
| 200 mg tablet Brand | $0.0801 | $2.40 / 30 tablets | ||
The lowest cost per tablet is 25 mg tablet at $0.0270. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Subvenite vs generic lamotrigine
Generics have the same active ingredient, strength and form, and FDA requires them to work the same way. What pharmacies pay for each, same quantity:
| Strength | Brand | Generic | Brand costs |
|---|---|---|---|
| 25 mg tablet | $0.81 | $0.81 | - |
| 100 mg tablet | $1.45 | $1.45 | - |
| 150 mg tablet | $2.06 | $2.06 | - |
| 200 mg tablet | $2.40 | $2.40 | - |
Supply status: shortages & recalls
Shortages
- Lamotrigine, Tablet, Extended Release, 100 mg (NDC 49884-563-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 25 mg (NDC 49884-561-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 250 mg (NDC 49884-604-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 300 mg (NDC 49884-605-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 50 mg (NDC 49884-562-11)Discontinuation of the manufacture of the drug
- Lamotrigine, Tablet, Extended Release, 200 mg (NDC 49884-564-11)Discontinuation of the manufacture of the drug
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 13 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Subvenite
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use SUBVENITE® safely and effectively. See full prescribing information for SUBVENITE®.SUBVENITE (lamotrigine) oral suspensionInitial U.S. Approval: 1994
WARNING: SERIOUS SKIN RASHES
SUBVENITE can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.3% to 0.8% in pediatric patients (aged 2 to 17 years) and 0.08% to 0.3% in adults receiving lamotrigine. One rash-related death was reported in a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking lamotrigine as adjunctive therapy. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate.
In addition to age, factors that may increase the risk of occurrence or the severity of rash caused by lamotrigine include (1) coadministration of lamotrigine with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of SUBVENITE, (3) exceeding the recommended dose escalation for SUBVENITE, or (4) the presence of the HLA-B*1502 allele. However, cases have occurred in the absence of these factors.
Nearly all cases of life-threatening rashes caused by lamotrigine have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have occurred after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy cannot be relied upon as means to predict the potential risk heralded by the first appearance of a rash.
Although benign rashes are also caused by lamotrigine, it is not possible to predict reliably which rashes will prove to be serious or life threatening. Accordingly, SUBVENITE should ordinarily be discontinued at the first sign of rash, unless the rash is clearly not drug related. Discontinuation of treatment may not prevent a rash from becoming life threatening or permanently disabling or disfiguring [see Warnings and Precautions (5.1)].
WARNING: SERIOUS SKIN RASHES
See full prescribing information for complete boxed warning.
Cases of life-threatening serious rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, and/or rash-related death have been caused by lamotrigine, the active ingredient in SUBVENITE. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include:
coadministration with valproate.
exceeding recommended initial dose of SUBVENITE.
exceeding recommended dose escalation for SUBVENITE.
presence of the HLA-B*1502 allele. (5.1)
Benign rashes are also caused by lamotrigine, the active ingredient in SUBVENITE; however, it is not possible to predict which rashes will prove to be serious or life threatening. SUBVENITE should be discontinued at the first sign of rash, unless the rash is clearly not drug related. (5.1)
Recent major changes (as listed on the label)
Boxed Warning | 08/2026 |
Warnings and Precautions (5.1) | 08/2026 |
Warnings and Precautions (5.4) | 08/2026 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA218879 · Owp Pharms
- First approved
- September 16, 2025 (1 year ago)
- Latest approved change
- July 17, 2026
- Approved label
- PDF, Jul 21, 2026
- Generic makers
- 27 approved generic applications on the market
- Last patent listed
- May 29, 2040
Subvenite questions
How much does subvenite cost without insurance?
Pharmacies pay about $2.06 for 30 tablets of subvenite 150 mg tablet ($0.0688 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $12.87. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Subvenite?
Yes: lamotrigine. Pharmacies pay from $0.81 for it. Compare lamotrigine prices.
Is subvenite in shortage?
Yes. 6 products are listed as in shortage or being discontinued (being discontinued). See which ones.
Has subvenite been recalled?
13 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the subvenite label last change?
The official label was last updated on October 21, 2026 (version 4). See what changed.
Talk about subvenite
No comments yet. Questions, tips, what worked for you - start the conversation.